{"ATC Code":"N02AA05","Abbreviation":"","Aliases":["Dihydrone","Dihydrohydroxycodeinone","Oxycodeinone","Dihydroxycodeinone","Oxicon","Diphydrone","Eucodalum","Oxycodon","Percobarb","Oxicodona"],"Biological Half-Life":"The apparent elimination half life of oxycodone is 3.2 hours for immediate release formulations and 4.5 hours for extended release formulations. Noroxycodone has a half life of 5.8 hours, oxymorphone has a half life of 8.8 hours, noroxymorphone has a half life of 9 hours.","CAS":"76-42-6","ChEBI":"CHEBI:7852","ChEMBL":"CHEMBL656","ChemicalClasses":["morphinan"],"Chirality":"absolute","Color/Form":"Rods from ethanol","Decomposition":"When heated to decomposition it emits toxic fumes of oxides of nitrogen.","Dosing Info":[{"Method":"Insufflated","Tiers":{"Common":{"Lower":10,"Upper":20},"Heavy":{"Lower":27.5,"Upper":40},"Light":{"Lower":5,"Upper":10},"Strong":{"Lower":20,"Upper":27.5},"Threshold":{"Lower":0.5,"Upper":5}},"Unit":"mg"},{"Method":"Oral","Tiers":{"Common":{"Lower":5,"Upper":11.25},"Heavy":{"Lower":20,"Upper":40},"Light":{"Lower":2,"Upper":5},"Strong":{"Lower":11.25,"Upper":20},"Threshold":{"Lower":0.5,"Upper":2}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Antitussive Agents; Opiates","Drug Indication":"Oxycodone is indicated for the treatment of moderate to severe pain. There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.","Drug Warnings":"/BOXED WARNING/ ADDICTION, ABUSE, AND MISUSE: Oxycodone Hydrochloride Capsules expose patients and other users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk prior to prescribing Oxycodone Hydrochloride Capsules and monitor all patients regularly for the development of these behaviors and conditions.","DrugClasses":["opioid"],"European Community (EC) Number":"200-960-2","FDA Pharmacological Classification":"CD35PMG570","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Antitussive Agents; Opiates","IUPACName":"(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one","InChI":"InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1","InChIKey":"BRUQQQPBMZOVGD-XFKAJCMBSA-N","MeSH Pharmacological Classification":"Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)","Melting Point":"219 °C","MolecularFormula":"C\u003csub\u003e18\u003c/sub\u003eH\u003csub\u003e21\u003c/sub\u003eNO\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"315.4 g/mol","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Oxycodone acts directly on a number of tissues not related to its analgesic effect. These tissues include the respiratory centre in the brain stem, the cough centre in the medulla, muscles of the pupils, gastrointestinal tract, cardiovascular system, endocrine system, and immune system. Oxycodone's effect on the respiratory centre is dose dependant respiratory depression. The action on the cough centre is suppression of the cough reflex. Pupils become miopic or decrease in size, peristalsis of the gastrointestinal tract slows, and muscle tone in the colon may increase causing constipation. In the cardiovascular system histamine may be released leading to pruritis, red eyes, flushing, sweating, and decreased blood pressure. Endocrine effects may include increased prolactin, decreased cortisol, and decreased testosterone. It is not yet known if the effects of opioids on the immune system are clinically significant.","Physical Description":"Solid","PubChemId":5284603,"Record Description":["Oxycodone is a semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain. It has a role as an opioid analgesic, a mu-opioid receptor agonist and an antitussive. It is an organic heteropentacyclic compound and a semisynthetic derivative. It is functionally related to a thebaine. It is a conjugate base of an oxycodone(1+). It derives from a hydride of a morphinan.","Oxycodone is a DEA Schedule II controlled substance. Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence.","Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period. The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.","Oxycodone is an Opioid Agonist. The mechanism of action of oxycodone is as a Full Opioid Agonist.","Oxycodone is a semisynthetic, moderately potent, orally available opioid that is widely used for acute or chronic management of moderate- or moderately severe pain either alone or in combination with acetaminophen. Oxycodone by itself has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury. However, the combination of oxycodone with acetaminophen has been linked to many cases of acute liver failure caused by unintentional overdose with acetaminophen.","Oxycodone has been reported in Papaver somniferum with data available.","Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","OXYCODONE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 4 approved and 29 investigational indications. This drug has a black box warning from the FDA.","Oxycodone is only found in individuals that have used or taken this drug. It is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.","A semisynthetic derivative of CODEINE.","See also: Oxycodone Hydrochloride (has salt form); Oxycodone Terephthalate (has salt form); Oxycodone hydrochloride trihydrate (is active moiety of) ... View More ...","Oxycodone is a semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain. It has a role as an opioid analgesic, a mu-opioid receptor agonist and an antitussive. It is an organic heteropentacyclic compound and a semisynthetic derivative. It is functionally related to a thebaine. It is a conjugate base of an oxycodone(1+). It derives from a hydride of a morphinan.","LiverTox|Analgesic|Moderate pain|Opiate"],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Oxycodone"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q407535"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00497"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/5284603"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.4447649.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL656"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7852"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=76-42-6"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0014640"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C08018"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/CD35PMG570"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5023407"}],"Reported Fatal Dose":"... We evaluated 1014 fatality cases involving oxycodone (OXC) for evidence of enhanced toxicity associated with multiple drug-drug interactions. We previously reported on these cases, and we classified them by a standardized method into groups that distinguished cases unrelated to drug abuse from those related to drug abuse, cases that involved only OXC from cases involving multiple drugs, drug-induced fatalities from drug-related fatalities, and cases in which the specific drug product OxyContin (oxycodone HCl controlled-release) Tablets were identified from cases where OxyContin was not identified. Our working hypothesis was that OXC in combination with other centrally acting drugs is more toxic than OXC alone, evidenced by the finding of lower mean blood concentrations of OXC in multiple-drug-induced deaths compared to single (OXC only)-drug-induced deaths. Assessment of blood levels determined by specific assay methodology (primarily gas chromatography-mass spectrometry) in these cases provided the following mean postmortem concentrations of OXC: multiple-drug-induced deaths, OxyContin identified, 0.93 ug/mL (N = 167); multiple-drug-induced deaths, OxyContin not identified, 0.73 ug/mL (N = 579); single (OXC)-drug-induced deaths, OxyContin identified, 1.55 ug/mL (N = 12); and single (OXC)-drug-induced deaths, OxyContin not identified, 1.70 ug/mL (N = 15). Overall, mean OXC concentration trends were as follows: single (OXC)-drug-induced, drug-abuse deaths \u003e multiple-drug-induced drug-abuse deaths \u003e drug-related drug-abuse deaths approximately deaths unrelated to drug abuse; and deaths in which OxyContin was identified approximately deaths in which OxyContin was not identified, whether the deaths involved oxycodone alone or multiple drugs. Drug abuse patterns in the multiple-drug-induced cases were complex. Over 135 drugs that were considered to be plausibly contributory to enhanced toxicity were identified in body fluids and tissues. Evaluation of mean OXC blood concentrations in cases that contained one, two, three, four, five, and six or more contributory drugs in combination demonstrated consistently lower mean OXC concentrations than those cases in which OXC was the only drug identified. A smaller number of cases were evaluated in the multiple-drug-induced groups in which OXC was paired with a single other contributory drug. The overall mean OXC concentration for these cases was 0.71 ug/mL (N = 90) as compared to 1.64 ug/mL (N = 27) for the cases in the single drug-induced groups. The consistent finding of lower mean OXC blood levels associated with multiple-drug-induced fatalities supports the stated hypothesis that OXC in combination with other centrally active drugs is more toxic than when OXC was the only drug involved.  ...","SMILES":"CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O","Salts":["phosphate","hydrochloride"],"Solubility":"166mg/mL","Stability/Shelf Life":"Stable under recommended storage conditions. /Oxycodone hydrochloride/","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="95.392mm" version="1.2" viewBox="0 0 75.788 95.392" width="75.788mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="96.0" stroke="none" width="76.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="74.768" x2="70.362" y1="83.374" y2="73.105"/>
                  
            <line class="bond" id="mol1bnd2" x1="68.837" x2="69.064" y1="65.519" y2="54.231"/>
                  
            <line class="bond" id="mol1bnd3" x1="69.064" x2="42.343" y1="54.231" y2="54.231"/>
                  
            <path class="bond" d="M28.96 61.547l.35 .607l18.887 -8.273h-5.247h-3.505z" fill="#000000" id="mol1bnd4" stroke="none"/>
                  
            <line class="bond" id="mol1bnd5" x1="29.135" x2="16.029" y1="61.851" y2="69.369"/>
                  
            <line class="bond" id="mol1bnd6" x1="16.029" x2="16.029" y1="69.369" y2="84.711"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="17.245" x2="6.708" y1="85.418" y2="91.48"/>
                        
                <line x1="16.029" x2="5.492" y1="83.304" y2="89.366"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.708" x2="11.976500000000001" y1="91.48" y2="88.44900000000001"/>
                <line class="hi" stroke="#FF0D0D" x1="5.492000000000001" x2="10.7605" y1="89.366" y2="86.33500000000001"/>
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="16.029" x2="29.135" y1="84.711" y2="92.331"/>
                  
            <line class="bond" id="mol1bnd9" x1="29.135" x2="42.343" y1="92.331" y2="84.711"/>
                  
            <line class="bond" id="mol1bnd10" x1="42.343" x2="42.343" y1="84.711" y2="69.369"/>
                  
            <line class="bond" id="mol1bnd11" x1="29.135" x2="42.343" y1="61.851" y2="69.369"/>
                  
            <line class="bond" id="mol1bnd12" x1="42.343" x2="55.551" y1="69.369" y2="61.851"/>
                  
            <path class="bond" d="M55.725 61.546l-.347 .609l9.392 6.878l.832 -1.461l.832 -1.462z" fill="#000000" id="mol1bnd13" stroke="none"/>
                  
            <path class="bond" d="M55.551 62.201c-.175 -.0 -.35 -.175 -.35 -.35v-6.653v-.0h.7v.0v6.658c.0 .175 -.175 .35 -.35 .35zM55.201 53.27v-6.659c.0 -.0 .175 -.35 .35 -.35c.175 -.0 .35 .175 .35 .35v6.655v-.0h-.7z" fill="#000000" id="mol1bnd14" stroke="none"/>
                  
            <line class="bond" id="mol1bnd15" x1="55.551" x2="42.343" y1="46.611" y2="38.889"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="29.135" x2="42.343" y1="46.611" y2="38.889"/>
                        
                <line x1="29.14" x2="39.905" y1="43.783" y2="37.49"/>
                      
            </g>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="28.785" x2="29.485" y1="61.851" y2="61.851"/>
                        
                <line x1="28.535" x2="29.735" y1="59.673" y2="59.673"/>
                        
                <line x1="28.285" x2="29.985" y1="57.496" y2="57.496"/>
                        
                <line x1="28.035" x2="30.235" y1="55.319" y2="55.319"/>
                        
                <line x1="27.785" x2="30.486" y1="53.142" y2="53.142"/>
                        
                <line x1="27.535" x2="30.736" y1="50.965" y2="50.965"/>
                        
                <line x1="27.285" x2="30.986" y1="48.788" y2="48.788"/>
                        
                <line x1="27.035" x2="31.236" y1="46.611" y2="46.611"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="29.135" x2="16.029" y1="46.611" y2="38.889"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="16.029" x2="16.029" y1="23.751" y2="38.889"/>
                        
                <line x1="18.467" x2="18.467" y1="25.153" y2="37.495"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="16.029" x2="29.135" y1="23.751" y2="16.131"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="42.343" x2="29.135" y1="23.751" y2="16.131"/>
                        
                <line x1="39.905" x2="29.14" y1="25.159" y2="18.948"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="42.343" x2="42.343" y1="38.889" y2="23.751"/>
                  
            <line class="bond" id="mol1bnd23" x1="16.029" x2="6.097" y1="23.751" y2="18.037"/>
                  
            <line class="bond" id="mol1bnd24" x1="2.813" x2="2.796" y1="12.229" y2=".911"/>
                  
            <line class="bond" id="mol1bnd25" x1="16.029" x2="8.383" y1="38.889" y2="50.161"/>
                  
            <g class="bond" id="mol1bnd26">
                        
                <line stroke="#000000" x1="15.731" x2="16.327" y1="69.553" y2="69.185"/>
                        
                <line stroke="#FF0D0D" x1="14.313" x2="15.281" y1="67.674" y2="67.076"/>
                        
                <line stroke="#FF0D0D" x1="12.895" x2="14.235" y1="65.795" y2="64.967"/>
                        
                <line stroke="#FF0D0D" x1="11.477" x2="13.189" y1="63.916" y2="62.858"/>
                        
                <line stroke="#FF0D0D" x1="10.059" x2="12.144" y1="62.037" y2="60.749"/>
                        
                <line stroke="#FF0D0D" x1="8.641" x2="11.098" y1="60.158" y2="58.641"/>
                        
                <line stroke="#FF0D0D" x1="7.223" x2="10.052" y1="58.279" y2="56.532"/>
                      
            </g>
                  
            <path class="bond" d="M42.519 69.066l-.352 .606l9.236 6.89l.836 -1.439l.837 -1.439z" fill="#000000" id="mol1bnd27" stroke="none"/>
                  
            <path class="atom" d="M70.7 71.819h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M5.078 92.308q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .566 .256 1.328zM1.215 92.308q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M5.078 16.148q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .566 .256 1.328zM1.215 16.148q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm20" stroke="none"/>
                  
            <path class="atom" d="M8.433 53.415q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM4.569 53.415q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" id="mol1atm22" stroke="none"/>
                  
            <g class="atom" id="mol1atm23">
                        
                <path d="M57.777 77.026q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM53.914 77.026q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" stroke="none"/>
                        
                <path d="M62.084 79.479h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.071h2.513v-2.071h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="70.362" x2="72.565" y1="73.105" y2="78.23949999999999"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="68.837" x2="68.9505" y1="65.519" y2="59.875"/>
            <line class="hi" id="mol1bnd23" stroke="#FF0D0D" x1="6.097000000000001" x2="11.063" y1="18.037" y2="20.894"/>
            <line class="hi" id="mol1bnd24" stroke="#FF0D0D" x1="2.813" x2="2.8045" y1="12.229" y2="6.569999999999999"/>
            <line class="hi" id="mol1bnd25" stroke="#FF0D0D" x1="8.383" x2="12.206" y1="50.161" y2="44.525000000000006"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Narcotics; Analgesics, Opioid","Title":"Oxycodone","UNII":"CD35PMG570","Wikidata":"Q407535","XLogP":1.2}